Cardiometabolic Health: The Missing Piece in Most Cardiovascular Evaluations

The rapid adoption of glucagon-like peptide-1 receptor agonists as cardiometabolic therapeutics has produced meaningful improvements in standard metabolic markers and demonstrated landmark reductions in major adverse cardiovascular events. Yet the monitoring infrastructure surrounding these medications has not kept pace with the physiologic complexity they introduce. Analysis of 63.4 million GLP-1 prescriptions over a six year period reveals that cardiologists write 0.4 percent of all prescriptions, while primary care physicians and advanced practice providers manage the overwhelming majority of patients on these potent metabolic agents within monitoring frameworks designed for glycemic and weight management oversight. Three significant physiologic gaps remain unaddressed within the current standard of care: sarcopenic metabolic compromise affecting lean muscle mass preservation, autonomic disruption evidenced by measurable reductions in heart rate variability and elevations in resting heart rate, and progressive micronutrient depletion during sustained appetite suppression. This paper presents a systems based physiologic framework for comprehensive cardiovascular monitoring and management of patients receiving GLP-1 receptor agonist therapy, grounded in published peer reviewed evidence and applied through the clinical model of Advanced Functional Cardiovascular Care. The position advanced is that true cardiometabolic care in the GLP-1 era requires evaluation of the vascular, autonomic, body composition, and cellular substrate dimensions of cardiovascular health that current guidelines and standard monitoring frameworks were not designed to reach.